

**Supplementary Table 1.** GRADE assessment of various outcomes and co-variates

| Outcome   | OR    | 95% CI     | P-value      | Heterogeneity            | No. of studies  | No. of participants                                 | GRADE assessment* |
|---|-------|------------|--------------|--------------------------|---|---|-------------------|
| Baseline DM   | 6.00  | 2.21–16.31 | <0.001       | $I^2=98.92, P\leq 0.001$ | 7 (5 cohort studies, 1 cross-sectional, 1 case control) | NAFLD: 946/8,175<br>Control: 212,467/20,434,403     | M (HMLHL)         |
| Current GDM   | 3.23  | 1.97–5.31  | <0.001       | $I^2=81.96, P\leq 0.001$ | 6 (5 cohort studies, 1 cross-sectional)                 | NAFLD: 1,408/6,184<br>Control: 1,308,369/20,407,018 | M (MMVLHL)        |
| History of GDM  | 3.78  | 2.21–6.44  | <0.001       | $I^2=64.87, P=0.02$      | 5 (4 cohort studies, 1 cross-sectional)                 | NAFLD: 198/374<br>Control: 235/1,710                | M (LLMHL)         |
| Baseline HTN  | 3.75  | 2.13–6.59  | $\leq 0.001$ | $I^2=85.34, P<0.001$     | 4 (3 cohort studies, 1 cross-sectional)                 | NAFLD: 953/6,131<br>Control: 565,806/18,455,399     | M (HMMHL)         |
| GHTN  | 1.83  | 1.03–3.26  | 0.041        | $I^2=43.81, P=0.18$      | 2 (2 cohort studies)                                    | NAFLD: 350/5,840<br>Control: 717,805/18,453,575     | M (HMMHL)         |
| Pre-eclampsia   | 3.24  | 2.21–4.75  | $\leq 0.001$ | $I^2=28.77, P=0.25$      | 3 (2 cohort studies, 1 cross-sectional)                 | NAFLD: 65/414<br>Control: 54,676/1,968,884          | M (HMMHL)         |
| Premature birth   | 2.02  | 1.44–2.85  | <0.001       | $I^2=60.56, P=0.06$      | 4 (3 cohort studies, 1 cross-sectional)                 | NAFLD: 557/6,054<br>Control: 948,015/20,412,433     | M (HMLHL)         |
| Large for gestational age birth                                 | 2.01  | 1.72–2.37  | <0.001       | $I^2=7.34, P=0.30$       | 2 (2 cohort studies)                                    | NAFLD: 317/5,758<br>Control: 489,821/18,453,880     | M (MMHHL)         |
| Composite outcome of pre-eclampsia, eclampsia or HELLP syndrome | 3.91  | 2.71–5.64  | <0.001       | $I^2=54.30, P=0.09$      | 4 (3 cohort studies, 1 cross-sectional)                 | NAFLD: 970/6,054<br>Control: 767,721/20,422,259     | M (HMMHL)         |
| Low birth weight  | 1.55  | 0.45–5.33  | 0.49         | $I^2=88.22, P=0.004$     | 2 (1 cohort studies, 1 cross-sectional)                 | NAFLD: 29/214<br>Control: 64,420/1,960,775          | M (MLLHL)         |
| Fetal death   | 1.15  | 0.86–1.55  | 0.34         | Not applicable           | 1 (1 cohort study)                                      | NAFLD: 45/5,640<br>Control: 127,730/18,453,375      | M (HLHL)          |
| IUGR  | 0.88  | 0.44–1.77  | 0.73         | $I^2=78.26, P=0.03$      | 2 (2 cohort studies)                                    | NAFLD: 101/5,840<br>Control: 372,930/18,453,575     | M (HVLHL)         |
| History of abortion or miscarriage                              | 1.15  | 1.02–1.30  | 0.02         | $I^2<0.001, P=0.64$      | 2 (2 cross-sectional)                                   | NAFLD: 1,304/1,870<br>Control: 2,989/4,614          | M (HMMHL)         |
| LSCS  | 2.05  | 1.19–3.53  | 0.01         | $I^2=89.85, P<0.001$     | 3 (2 cohort studies, 1 cross-sectional)                 | NAFLD: 2,982/5,854<br>Control: 6,359,337/20,414,150 | M (HMLHL)         |
| Obesity BMI $\geq 30$ kg/m <sup>2</sup>                         | 8.44  | 8.00–8.89  | $\leq 0.001$ | $I^2<0.001, P=0.36$      | 2 (2 cohort studies)                                    | NAFLD: 2,284/5,732<br>Control: 1,507,050/20,151,741 | H (HHHHL)         |
| Hispanic background   | 2.38  | 2.25–2.51  | $\leq 0.001$ | $I^2<0.001, P=0.95$      | 3 (3 cohort studies)                                    | NAFLD: 2,087/5,705<br>Control: 3,561,679/18,453,777 | M (MHHHL)         |
| Post-partum hemorrhage  | 2.03  | 1.83–2.27  | <0.001       | Not applicable           | 1 (1 cohort study)                                      | NAFLD: 355/5,640<br>Control: 589,670/18,453,375     | M (HHHL)          |
| Maternal death  | 17.80 | 7.39–42.88 | <0.001       | Not applicable           | 1 (1 cohort study)                                      | NAFLD: 5/5,640<br>Control: 920/18,453,375           | M (HLHL)          |
| Vaginal delivery  | 1.02  | 0.65–1.58  | 0.95         | Not applicable           | 1 (1 cross-sectional)                                   | NAFLD: 66/104<br>Control: 296/469                   | M (HLHL)          |

GRADE, Grading of Recommendations, Assessment, Development and Evaluations; OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; NAFLD, non-alcoholic fatty liver disease; GDM, gestational diabetes mellitus; HTN, hypertension; GHTN, gestational hypertension; HELLP, haemolysis, elevated liver enzymes, low platelet count; IUGR, intrauterine growth restriction; LSCS, low section caesarean section; BMI, body mass index.

\*Grade score ranking: V, very low; L, low; M, moderate; and H, high. Grade assessment domains: Risk of bias, Imprecision, Inconsistency, Indirectness, Publication bias. Very low, the true effect is probably markedly different from the estimated effect; Low, the true effect might be markedly different from the estimated effect; Moderate, the authors believe that the true effect is probably close to the estimated effect; and High, the authors have a lot of confidence that the true effect is similar to the estimated effect.